Grífols buys part of Novartis Diagnostics for $1.68 billion
The Catalan pharmaceutical company Grífols, based in Greater Barcelona, has bought part of the diagnostics unit of Swiss multinational Novartis for $1,675 million. Grífols has acquired products and ‘in vitro’ technology applied to diagnoses in the fields of blood transfusion and immunology, along with a production plant in California and offices in the US, Switzerland and Hong Kong. With the acquisition, the Grífols Diagnostic Division will represent $1 billion, 20% of the Catalan group’s total revenues. Grífols is the world’s third largest company in the production of blood-plasma derivatives. In the first half of 2013, Grífols registered a profit of €182.2 million, an increase of 36.9% on the same period of 2012.